Cartridge and Medical Apparatus - A face mask that delivers light therapy to people suffering with diabetic retinopathy
- Submitting institution
-
University of Northumbria at Newcastle
- Unit of assessment
- 32 - Art and Design: History, Practice and Theory
- Output identifier
- 40674763
- Type
- F - Patent/ published patent application
- Patent registration number
- EP2686066 (B1)
- Month
- September
- Year
- 2015
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
2
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Globally, there are approximately 148 million people with diabetic eye disease, the leading cause of blindness for working age adults (Keenan et al., 2013). Current physician administered interventions include regular injections into the eye (over £13,000 p/a) and laser treatment (over £7,800 p/a) both are costly and invasive. The invention embodied in this patent is a patient empowering, self-administered treatment (costing £900-1250 p/a per patient) that: has secured £19.5m investment, has been trialled by 674 patients, is non-invasive and 94% effective, is inexpensive compared with other treatments potentially saving the NHS up to £300m p/a. The research associated with this patent was carried out in collaboration with Polyphotonix ltd and is underpinned by a multiple perspective problem framing method (MPPF) developed and previously published by English (e.g. English 2010). By adopting a MPPF method to synthesise and interpret data relating to scientific and medical research; organic LED technology; human factors; sleep habits and behaviour; product/service requirements; diabetes and influencing factors, six ‘Cornerstones of Innovation’ (English 2007) were identified to frame the potential for creative product design. These cornerstones describe a “Patient-administered, professionally monitored, washable, dose controlled light treatment device located consistently over the diabetic eye during normal comfortable sleep” and are the basis of the internationally granted patent submitted and a commercially available product the Noctura 400, www.noctura.com The originality of the output is independently recognised through substantive examination by intellectual property offices in Europe, China, USA, Mexico, Japan, Australia, Canada and South Korea leading to the grant of patents with the following patent numbers: Europe: EP2686066 (B1), 2015-09-23, China: CN103596621 (B), 2016-05-18, Australia: AU2012228054 (B2), 2016-07-07, Mexico: MX343529 (B), 2016-11-09, Japan: JP6241878 (B2), 2017-12-06, USA: US9849303 (B2), 2017-12-26, South Korea KR102043313 (B1) 2019-11-11, Canada: CA2829816 (C) 2020-05-12.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
